This site uses cookies. By using this site you agree to receiving cookies. View Policy.

57%

The global cost of diabetes is an unsustainable $1.25 trillion: 1.8% of global GDP. Spotlight Consultations’ evidence-based Spotlight-AQ aims to develop a new approach that helps reduce expenditure and healthcare burden whilst improving the quality of care & health outcomes through subscription-based clinic tools.

  • We estimate our global addressable market at £1.6bn (across a range of products)
  • Clinical trials expected to start in 2021
  • Patent pending in the UK
  • Aim to Launch in pre-diabetes, T2 and T1 diabetes: English & Mandarin

Idea

10% of global health expenditure p.a ($760bn) is spent on diabetes. This is predicted to rise to $825bn by 2030. Indirect costs from premature death, disability and diabetes-related health complications are estimated to add an additional 35% to this number. Intangible costs are less visible: worry, anxiety, discomfort, pain, loss of independence, fears for health.

Once it's fully developed Spotlight-AQ aims to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. Easy-to-understand visual graphics show results and therapy options that are shared with healthcare professionals, facilitating shared decision-making to meet individual needs.

Once live, Spotlight-AQ will be charged at £1 per user. Our subscription model could provide an independent operating platform scalable to an entire national healthcare service e.g. individual clinics & doctors. We aim to produce digital health tools that are innovative; scale to different national and international health services, different languages and contain inbuilt audio/colour versions for people with low literacy. The investment will support early revenue generation, team expansion, R&D of tools in CVD, IBD, chronic pain and cancers.

Next steps: begin clinical trials in '21, launch to UK market followed by China & US with the guidance of an expert non-executive board.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Spotlight Consultations pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

This pitch is approved by Crowdcube

This pitch is approved as a financial promotion by Crowdcube Capital Limited. Every pitch on Crowdcube is reviewed to ensure it is fair, clear and not misleading.

As part of our commitment to investor transparency, Crowdcube’s Due Diligence Charter outlines the analysis and verification that is conducted on equity fundraises on Crowdcube by our legal and compliance professionals.

Read more

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Spotlight Consultations has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.